UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 37

Sortiert nach

Blocking of Interleukin-17 during Reactivation of Experimental Arthritis Prevents Joint Inflammation and Bone Erosion by Decreasing RANKL and Interleukin-1

The American journal of pathology, 2005-07, Vol.167 (1), p.141-149

2005

Link zum Volltext

Verfügbarkeit prüfen

Identification of a Cross-reactive Epitope Widely Present in Lipopolysaccharide from Enterobacteria and Recognized by the Cross-protective Monoclonal Antibody WN1 222-5

The Journal of biological chemistry, 2003-07, Vol.278 (28), p.25618-25627

2003

Link zum Volltext

Verfügbarkeit prüfen

Interleukin-17 acts independently of TNF-alpha under arthritic conditions

Journal of Immunology, 2006-05, Vol.176 (10), p.6262-6269

2006

Link zum Volltext

Verfügbarkeit prüfen

Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis

Bioorganic & medicinal chemistry letters, 2004-07, Vol.14 (13), p.3595-3599

2004

Link zum Volltext

Verfügbarkeit prüfen

Pyrazoloheteroaryls: Novel p38α MAP kinase inhibiting scaffolds with oral activity

Bioorganic & medicinal chemistry letters, 2006-01, Vol.16 (2), p.262-266

2006

Link zum Volltext

Verfügbarkeit prüfen

Monoclonal antibody to endotoxin attenuates hemorrhage-induced lung injury and mortality in rats

Critical care medicine, 1997-06, Vol.25 (6), p.1030-1036

1997

Link zum Volltext

Verfügbarkeit prüfen

Role of repetitive antigen patterns for induction of antibodies against antibodies

The Journal of experimental medicine, 1997-05, Vol.185 (10), p.1785-1792

1997

Link zum Volltext

Verfügbarkeit prüfen

SAR of 4-hydroxypiperidine and hydroxyalkyl substituted heterocycles as novel p38 map kinase inhibitors

Bioorganic & medicinal chemistry letters, 2000-06, Vol.10 (11), p.1261-1264

2000

Link zum Volltext

Verfügbarkeit prüfen

Interleukin‐1 drives pathogenic Th17 cells during spontaneous arthritis in interleukin‐1 receptor antagonist–deficient mice

Arthritis and rheumatism, 2008-11, Vol.58 (11), p.3461-3470

2008

Link zum Volltext

Verfügbarkeit prüfen

SAR of benzoylpyridines and benzophenones as p38α MAP kinase inhibitors with oral activity

Bioorganic & medicinal chemistry letters, 2004-07, Vol.14 (13), p.3601-3605

2004

Link zum Volltext

Verfügbarkeit prüfen

SAR of 2,6-diamino-3,5-difluoropyridinyl substituted heterocycles as novel p38 MAP kinase inhibitors

Bioorganic & medicinal chemistry letters, 2002-08, Vol.12 (16), p.2109-2112

2002

Link zum Volltext

Verfügbarkeit prüfen

Interleukin‐6 is produced by bone and modulated by parathyroid hormone

Journal of bone and mineral research, 1989-08, Vol.4 (4), p.633-638

1989

Link zum Volltext

Verfügbarkeit prüfen

SAR of 2,6-diamino-3,5-difluoropyridinyl substituted heterocycles as novel p38MAP kinase inhibitors

Bioorganic & medicinal chemistry letters, 2002-08, Vol.12 (16), p.2109-2112

2002

Link zum Volltext

Verfügbarkeit prüfen

T cell lessons from the RA synovium SCID mouse model: synovial tissue rich in CD3 T cells lacks response to CTLA4-Ig, but is successfully treated with anti-IL-17 antibodies

Annals of the rheumatic diseases, 2011-03, Vol.70 (Suppl 2), p.A73-A74

2011

Link zum Volltext

Verfügbarkeit prüfen

T cell lessons from the rheumatoid arthritis synovium SCID mouse model: CD3-rich synovium lacks response to CTLA-4ig but is successfully treated by interleukin-17 neutralization

Arthritis and rheumatism, 2012-06, Vol.64 (6), p.1762-1770

2012

Link zum Volltext

Verfügbarkeit prüfen

Pyrazoloheteroaryls: novel p38alpha MAP kinase inhibiting scaffolds with oral activity

Bioorganic & medicinal chemistry letters, 2006-01, Vol.16 (2), p.262-266

2006

Link zum Volltext

Verfügbarkeit prüfen

SAR of benzoylpyridines and benzophenones as p38alpha MAP kinase inhibitors with oral activity

Bioorganic & medicinal chemistry letters, 2004-07, Vol.14 (13), p.3601

2004

Link zum Volltext

Verfügbarkeit prüfen

Blocking of lnterleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1

The American journal of pathology, 2005, Vol.167 (1), p.141-149

2005

Link zum Volltext

Verfügbarkeit prüfen

Interleukin-17 Acts Independently of TNF-{alpha} under Arthritic Conditions

The Journal of immunology (1950), 2006-05, Vol.176 (10), p.6262

2006

Link zum Volltext

Verfügbarkeit prüfen

Pyrazoloheteroaryls: Novel p38α MAP Kinase Inhibiting Scaffolds with Oral Activity

ChemInform, 2006-04, Vol.37 (16), p.no-no

2006

Link zum Volltext

Verfügbarkeit prüfen

Novel p38 Inhibitors with Potent Oral Efficacy in Several Models of Rheumatoid Arthritis

ChemInform, 2004-10, Vol.35 (43), p.no-no

2004

Link zum Volltext

Verfügbarkeit prüfen

SAR of Benzoylpyridines and Benzophenones as p38α MAP Kinase Inhibitors with Oral Activity

ChemInform, 2004-10, Vol.35 (43), p.no-no

2004

Link zum Volltext

Verfügbarkeit prüfen

SAR of 2,6-Diamino-3,5-difluoropyridinyl Substituted Heterocycles as Novel p38 MAP Kinase Inhibitors

ChemInform, 2002-12, Vol.33 (48), p.149-149

2002

Link zum Volltext

Verfügbarkeit prüfen

ChemInform Abstract: SAR of 4-Hydroxypiperidine and Hydroxyalkyl Substituted Heterocycles as Novel p38 Map Kinase Inhibitors

ChemInform, 2000-09, Vol.31 (39), p.no-no

2000

Link zum Volltext

Verfügbarkeit prüfen

Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safety

Pharmacology & therapeutics (Oxford), 2022-01, Vol.229, p.107925-107925, Article 107925

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 37

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(31)

Publikationsform

Artikel
(37)

Sprache

Englisch
(37)
Japanisch
(10)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Blocking of Interleukin-17 during Reactivation of Experimental Arthritis Prevents Joint Inflammation and Bone Erosion by Decreasing RANKL and Interleukin-1

Identification of a Cross-reactive Epitope Widely Present in Lipopolysaccharide from Enterobacteria and Recognized by the Cross-protective Monoclonal Antibody WN1 222-5

Interleukin-17 acts independently of TNF-alpha under arthritic conditions

Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis

Pyrazoloheteroaryls: Novel p38α MAP kinase inhibiting scaffolds with oral activity

Monoclonal antibody to endotoxin attenuates hemorrhage-induced lung injury and mortality in rats

Role of repetitive antigen patterns for induction of antibodies against antibodies

SAR of 4-hydroxypiperidine and hydroxyalkyl substituted heterocycles as novel p38 map kinase inhibitors

Interleukin‐1 drives pathogenic Th17 cells during spontaneous arthritis in interleukin‐1 receptor antagonist–deficient mice

SAR of benzoylpyridines and benzophenones as p38α MAP kinase inhibitors with oral activity

SAR of 2,6-diamino-3,5-difluoropyridinyl substituted heterocycles as novel p38 MAP kinase inhibitors

Interleukin‐6 is produced by bone and modulated by parathyroid hormone

SAR of 2,6-diamino-3,5-difluoropyridinyl substituted heterocycles as novel p38MAP kinase inhibitors

T cell lessons from the RA synovium SCID mouse model: synovial tissue rich in CD3 T cells lacks response to CTLA4-Ig, but is successfully treated with anti-IL-17 antibodies

T cell lessons from the rheumatoid arthritis synovium SCID mouse model: CD3-rich synovium lacks response to CTLA-4ig but is successfully treated by interleukin-17 neutralization

Pyrazoloheteroaryls: novel p38alpha MAP kinase inhibiting scaffolds with oral activity

SAR of benzoylpyridines and benzophenones as p38alpha MAP kinase inhibitors with oral activity

Blocking of lnterleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1

Interleukin-17 Acts Independently of TNF-{alpha} under Arthritic Conditions

Pyrazoloheteroaryls: Novel p38α MAP Kinase Inhibiting Scaffolds with Oral Activity

Novel p38 Inhibitors with Potent Oral Efficacy in Several Models of Rheumatoid Arthritis

SAR of Benzoylpyridines and Benzophenones as p38α MAP Kinase Inhibitors with Oral Activity

SAR of 2,6-Diamino-3,5-difluoropyridinyl Substituted Heterocycles as Novel p38 MAP Kinase Inhibitors

ChemInform Abstract: SAR of 4-Hydroxypiperidine and Hydroxyalkyl Substituted Heterocycles as Novel p38 Map Kinase Inhibitors

Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safety

Suchergebnisse filtern